TDP-43 Protein

TDP-43 Protein

Pathway Diagram

Overview

TAR DNA-binding protein 43 (TDP-43) is a highly conserved ribonucleoprotein that functions as an RNA/DNA-binding protein encoded by the TARDBP gene located on chromosome 6q21. With a molecular weight of approximately 43 kDa, TDP-43 is predominantly localized to the cell nucleus under normal physiological conditions, where it plays critical roles in transcriptional regulation and RNA processing. The protein consists of an N-terminal domain, two RNA recognition motifs (RRMs), and a C-terminal glycine-rich prion-like domain. TDP-43 has emerged as a central pathological hallmark of multiple neurodegenerative diseases, most notably amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD), where it accumulates in abnormal cytoplasmic inclusions within affected neurons.

Function/Biology

TDP-43 Protein

Pathway Diagram

Overview

TAR DNA-binding protein 43 (TDP-43) is a highly conserved ribonucleoprotein that functions as an RNA/DNA-binding protein encoded by the TARDBP gene located on chromosome 6q21. With a molecular weight of approximately 43 kDa, TDP-43 is predominantly localized to the cell nucleus under normal physiological conditions, where it plays critical roles in transcriptional regulation and RNA processing. The protein consists of an N-terminal domain, two RNA recognition motifs (RRMs), and a C-terminal glycine-rich prion-like domain. TDP-43 has emerged as a central pathological hallmark of multiple neurodegenerative diseases, most notably amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD), where it accumulates in abnormal cytoplasmic inclusions within affected neurons.

Function/Biology

Under normal conditions, TDP-43 executes diverse molecular functions essential for neuronal homeostasis. The protein functions as a splicing regulator, modulating the alternative splicing of numerous pre-mRNA transcripts through sequence-specific RNA binding via its RRM domains. TDP-43 also participates in microRNA biogenesis, particularly in the processing of pri-miRNAs to pre-miRNAs, thereby influencing gene expression at the post-transcriptional level. Additionally, TDP-43 functions in transcriptional repression of certain genes and plays roles in mRNA stability and localization within neurons.

The protein exhibits dynamic nucleocytoplasmic shuttling under normal conditions, with nuclear import mediated by importin-α/β heterodimers and nuclear export facilitated by chromosomal region maintenance 1 (CRM1). TDP-43 contains functional nuclear localization signals (NLS) and nuclear export signals (NES) that govern its subcellular distribution. The glycine-rich C-terminal domain, while not directly involved in RNA binding, serves as a protein interaction interface and possesses prion-like structural characteristics that become pathologically relevant during disease progression.

Role in Neurodegeneration

TDP-43 pathology represents a defining feature of approximately 97% of ALS cases and 45-50% of frontotemporal dementia cases, making it the most common pathological hallmark in these conditions. In Alzheimer's disease and Parkinson's disease, TDP-43 co-pathology occurs in 25-40% of cases and frequently coexists with other proteinopathies. The characteristic pathological feature involves abnormal cytoplasmic accumulation and aggregation of phosphorylated, ubiquitinated, and cleaved TDP-43 fragments. This pathological redistribution results in loss of normal nuclear TDP-43 function (loss-of-function mechanism) combined with potential gain-of-function toxicity from cytoplasmic aggregates.

The cytoplasmic mislocalization of TDP-43 impairs its normal splicing functions, leading to dysregulation of target transcripts including those encoding critical proteins for neuronal survival. Notably, aberrant TDP-43 splicing activity affects genes involved in RNA processing, synaptic function, and stress response pathways. Additionally, cytoplasmic TDP-43 aggregates may sequester other RNA-binding proteins, exacerbating cellular dysfunction through a dominant-negative mechanism.

Molecular Mechanisms

TDP-43 pathology involves a multi-step cascade beginning with aberrant phosphorylation at serine residues (particularly Ser409/410), catalyzed by kinases such as casein kinase 1δ. Phosphorylation promotes conformational changes facilitating the formation of pathological assemblies. Ubiquitination by ubiquitin ligases, particularly involving lysine residues, marks TDP-43 for proteasomal degradation while also promoting aggregate formation. Caspase-3 and calpain proteolysis generate C-terminal fragments (particularly ~25 kDa fragments) that possess increased aggregation propensity and neurotoxicity.

The prion-like domain of TDP-43 enables self-templating aggregation and pathological spreading between neurons, potentially through exosomal release and uptake, similar to mechanisms observed with other neurodegenerative proteinopathies. Mutations in TARDBP identified in familial ALS cases promote increased aggregation propensity and cytoplasmic localization, providing direct evidence linking TDP-43 dysfunction to neurodegeneration.

Clinical/Research Significance

TDP-43 pathology has prognostic and diagnostic value in neurodegenerative disease assessment. The distribution patterns of TDP-43 pathology correlate with clinical phenotypes in ALS and FTD spectrum disorders. Neuropathologically, TDP-43 aggregates serve as diagnostic criteria for primary age-related tauopathy (PART) and frontotemporal lobar degeneration (FTLD-TDP). Research efforts increasingly focus on developing biomarkers detecting phosphorylated or misfolded TDP-43 in cerebrospinal fluid and blood to enable early diagnosis and therapeutic monitoring.

Related Entities

TARDBP gene - Encodes TDP-43; mutations cause famil